In vivo patterns of BCL-2 family protein expression in breast carcinomas in relation to apoptosis

Journal of Pathology

Volumn 187, Issue 4, 1999, Pages 410-415

  Rochaix, Philippe ^a   Krajewski, Stanislaw ^b   Reed, John C ^b   Bonnet, Françoise ^c   Voigt, Jean Jacques ^a   Brousset, Pierre ^d  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b BURNHAM INSTITUTE   (United States)

^c Lab de Pharmacocinétique   (France)

^d CHU PURPAN   (France)

Author keywords

Apoptosis; Bcl 2 related proteins; Breast carcinoma; Oestrogen receptor; p53

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GRADING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IN SITU NICK-END LABELING; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033014030     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199903)187:4<410::AID-PATH266>3.0.CO;2-F     Document Type: Article

References (44)

1. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the Bcl-2 gene. Cancer Res 1994; 54: 3131-3135.
2. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of Bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
3. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
4. Selvakumaran M, Lin HK, Miyashita T, et al. Immediate early up-regulation of bax expression by p53 but not TGF beta 1 : a paradigm for distinct apoptotic pathways. Oncogene 1994; 9: 1791-1798.
5. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54: 2095-2097.
6. Ferneres G, Cuny M, Simony-Lafontaine J, et al. Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas. J Pathol 1997; 183: 204-211.
7. Teixeira C, Reed JC, Pratt C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-3907.
8. Wang TT, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995; 55: 2487-2489.
9. Wilson JW, Wakeling AE, Morris ID, Hickman JA, Dive C. MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage. Int J Cancer 1995; 61: 502-508.
10. Kandouz M, Siromachkova M, Jacob D, Chretien Marquet B, Therwath A, Gompel A. Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. Int J Cancer 1996; 68: 120-125.
11. Bargou RC, Daniel PT, Mapara MY, et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1996; 60: 854-859.
12. Gee JM, Robertson JF, Ellis IO, et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994; 59: 619-628.
13. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Marck EV. Prognostic value of Bcl-2 expression in invasive breast cancer. Br J Cancer 1995; 72: 354-360.
14. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein Bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995; 177: 49-55.
15. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene Bax in associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-4478.
16. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
17. Silvestrini R, Benini E, Veneroni S, et al. p53 and Bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996; 14: 1604-1610.
18. Mustonen M, Raunio H, Paakko P, Soini Y. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology 1997; 31: 347-354.
19. Del Bufalo D, Biroccio A, Leonetti C, Zupi G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J 1997; 11: 947-953.
20. Duenas-Gonzalez A, Abad-Hernandez MM, Cruz-Hernandez JJ, Gonzalez-Sarmiento R. Analysis of bcl-2 in sporadic breast carcinoma. Cancer 1997; 80: 2100-2108.
21. Hori M, Nogami T, Itabashi M, Yoshimi F, Ono H, Koizumi S. Expression of Bcl-2 in human breast cancer: correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis. Pathol Int 1997; 47: 757-762.
22. Elledge RM, Green S, Howes L, et al. Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. J Clin Oncol 1997; 15: 1916-1922.
23. Kapucuoglu N, Losi L, Eusebi V. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas. Virchows Arch 1997; 430: 17-22.
24. Kapranos N, Karaiosifidi H, Valavanis C, Kouri E, Vasilaros S. Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res 1997; 17: 2499-2505.
25. Sakakura C, Sweeney EA, Shirahama T, et al. Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide. Surg Today 1997; 27: 676-679.
26. Ogretmen B, Safa AR. Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistance MCF-7/Adr human breast cancer cells. Int J Cancer 1996; 67: 608-614.
27. Wagener C, Bargou RC, Daniel PT, et al. Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 1996; 67: 138-141.
28. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
29. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39: 741-748.
30. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994; 145: 1323-1336.
31. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994; 54: 5501-5507.
32. Krajewski S, Bodrug S, Krajewska M, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995; 146: 1309-1319.
33. Krajewski S, Krajewska M, Reed JC. Immunohistochemical analysis of in vivo pattern of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res 1996; 56: 2849-2855.
34. Vilain MO, Delobelle-Deroide A, Bloget F, et al. Immunohistochemical detection of estrogen and progesterone receptors in formalin-fixed, paraffin-embedded tissues after microwave treatment. Comparison with biochemical assay in a series of 123 breast carcinomas with determination of the positivety cut-off. Ann Pathol 1997; 17: 82-88.
35. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994; 14: 2068-2073.
36. Hsu CK, Rishi AK, Li XS, et al. Bcl-X(L) expression and its downregulation by a novel retinoid in breast carcinoma cells. Exp Cell Res 1997; 232: 17-24.
37. Olopade OI, Adeyanju MO, Safa AR, et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 1997; 3: 230-237.
38. Xerri L, Parc P, Brousset P, et al. Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol 1996; 92: 900-906.
39. Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 1995; 10: 2297-2305.
40. Reed JC. Balancing cell life and death: bax, apoptosis, and breast cancer. J Clin Invest 1996; 97: 2403-2404.
41. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerization with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-7838.
42. Chittenden T, Harrington EA, O'Connor R, et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995; 374: 733-736.
43. Kiefer MC, Brauer MJ, Powers VC, et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995; 374: 736-739.
44. Al Saati T, Clamens S, Cohen-Knafo E, et al. Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int J Cancer 1993; 55: 651-654.